Olufunmilayo Olopade to DNA Mutational Analysis
This is a "connection" page, showing publications Olufunmilayo Olopade has written about DNA Mutational Analysis.
Connection Strength
0.914
-
Whole-genome analysis of Nigerian patients with breast cancer reveals ethnic-driven somatic evolution and distinct genomic subtypes. Nat Commun. 2021 11 26; 12(1):6946.
Score: 0.173
-
Recurrent BRCA1 and BRCA2 mutations in breast cancer patients of African ancestry. Breast Cancer Res Treat. 2012 Jul; 134(2):889-94.
Score: 0.090
-
ColoSeq provides comprehensive lynch and polyposis syndrome mutational analysis using massively parallel sequencing. J Mol Diagn. 2012 Jul; 14(4):357-66.
Score: 0.090
-
Molecular analysis of colorectal tumors within a diverse patient cohort at a single institution. Clin Cancer Res. 2012 Jan 15; 18(2):350-9.
Score: 0.086
-
Novel germline PALB2 truncating mutations in African American breast cancer patients. Cancer. 2012 Mar 01; 118(5):1362-70.
Score: 0.085
-
Screening RAD51C nucleotide alterations in patients with a family history of breast and ovarian cancer. Breast Cancer Res Treat. 2010 Dec; 124(3):857-61.
Score: 0.079
-
Evidence for an ancient BRCA1 mutation in breast cancer patients of Yoruban ancestry. Fam Cancer. 2009; 8(1):15-22.
Score: 0.069
-
The impact of site-specific digital histology signatures on deep learning model accuracy and bias. Nat Commun. 2021 07 20; 12(1):4423.
Score: 0.042
-
Male breast cancer in Cowden syndrome patients with germline PTEN mutations. J Med Genet. 2001 Mar; 38(3):159-64.
Score: 0.041
-
Prevalence of Inherited Mutations in Breast Cancer Predisposition Genes among Women in Uganda and Cameroon. Cancer Epidemiol Biomarkers Prev. 2020 02; 29(2):359-367.
Score: 0.038
-
Effect of Oophorectomy on Survival After Breast Cancer in BRCA1 and BRCA2 Mutation Carriers. JAMA Oncol. 2015 Jun; 1(3):306-13.
Score: 0.028
-
Germline mutations in CDH1 are infrequent in women with early-onset or familial lobular breast cancers. J Med Genet. 2011 Jan; 48(1):64-8.
Score: 0.020
-
Genetic and functional analysis of CHEK2 (CHK2) variants in multiethnic cohorts. Int J Cancer. 2007 Dec 15; 121(12):2661-7.
Score: 0.016
-
Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: an update. Int J Cancer. 2006 May 01; 118(9):2281-4.
Score: 0.015
-
A comparison of bilateral breast cancers in BRCA carriers. Cancer Epidemiol Biomarkers Prev. 2005 Jun; 14(6):1534-8.
Score: 0.014
-
No evidence for core-binding factor CBFbeta as a leukemia predisposing factor in chromosome 16q22-linked familial AML. Leukemia. 2004 Apr; 18(4):881.
Score: 0.013
-
Sequence analysis of BRCA1 and BRCA2: correlation of mutations with family history and ovarian cancer risk. J Clin Oncol. 1998 Jul; 16(7):2417-25.
Score: 0.009
-
Preferential loss of expression of p16(INK4a) rather than p19(ARF) in breast cancer. Clin Cancer Res. 1996 Dec; 2(12):1993-8.
Score: 0.008